Milestone Pharmaceuticals Dividends and Buybacks

Dividend criteria checks 0/6

Milestone Pharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-23.0%

Buyback Yield

Total Shareholder Yield	-23.0%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?

Nov 06

Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

Jun 07

We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth

Jun 24

We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely

Feb 25

We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow

Aug 25

Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth

Apr 02

What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition

Jan 15

First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT

Nov 18

Milestone Pharmaceuticals EPS beats by $0.09

Nov 13

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if MIST's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MIST's dividend payments have been increasing.

Dividend Yield vs Market

Milestone Pharmaceuticals Dividend Yield vs Market

How does MIST dividend yield compare to the market?
Segment	Dividend Yield
Company (MIST)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.5%
Industry Average (Pharmaceuticals)	2.5%
Analyst forecast (MIST) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate MIST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MIST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate MIST's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MIST has not reported any payouts.

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 22:46
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Milestone Pharmaceuticals Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Patrick Trucchio	H.C. Wainwright & Co.
Christopher Howerton	Jefferies LLC
Yuchen Ding	Jefferies LLC

Milestone Pharmaceuticals Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Price target increased by 24% to US$13.00

Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?

Milestone Pharmaceuticals Appoints Joseph Papa to Its Board of Directors

Milestone Pharmaceuticals Inc., Annual General Meeting, Aug 28, 2024

Milestone Pharmaceuticals Inc. Refreshes Board of Directors

Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely

New minor risk - Market cap size

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

New minor risk - Profitability

Price target increased by 24% to US$13.00

Forecast to breakeven in 2026

New major risk - Shareholder dilution

Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Price target increased by 21% to US$13.00

Milestone Pharmaceuticals Inc. Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia

Milestone Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2024

Full year 2023 earnings: EPS misses analyst expectations

New major risk - Revenue and earnings growth

No longer forecast to breakeven

New minor risk - Shareholder dilution

Milestone Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $29.966667 million.

Milestone Pharmaceuticals Inc. Announces Plan to Resubmit NDA for Etripamil for the Treatment of Psvt

Price target decreased by 21% to US$10.75

Forecast to breakeven in 2026

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

Price target increased by 13% to US$16.00

Alta Advisers Sends a Letter to Milestone Pharmaceuticals

Insufficient new directors

New minor risk - Market cap size

Milestone Pharmaceuticals Inc. Announces Submission of New Drug Application to the U.S. FDA for Etripamil

Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?

New minor risk - Profitability

Price target increased by 12% to US$16.75

New minor risk - Share price stability

Milestone Pharmaceuticals Inc. Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in the Lancet

Price target decreased by 9.0% to US$14.20

Chief Commercial Officer recently bought US$94k worth of stock

We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

Milestone Pharmaceuticals Inc. Announces the Retirement of Francis Plat as Chief Scientific Officer, Effective December 31, 2022

Milestone Pharmaceuticals Inc. Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA Scientific Sessions 2022

Independent Non-Executive Director recently bought US$80k worth of stock

Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia

Price target increased to US$15.40

We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth

Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 Node-302 Study of Etripamil for the Treatment of Psvt

Milestone Pharmaceuticals Inc., Annual General Meeting, Jun 23, 2022

We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely

Milestone Pharmaceuticals Appoints David Bharucha as Chief Medical Officer

We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow

Consensus revenue estimates increase to US$15.0m

Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21

Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth

New 90-day low: US$6.52

New 90-day high: US$7.67

What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition

Milestone Pharmaceuticals Inc. Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT

First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT

Milestone Pharmaceuticals Inc. Announces Board Changes

Milestone Pharmaceuticals EPS beats by $0.09

New 90-day low: US$6.00

Milestone Pharmaceuticals Inc. Appoints Lisa Giles and Robert Wills to Board of Directors, Effective October 1, 2020

Milestone Pharmaceuticals Inc. announced that it has received $24.933448 million in funding from RTW Investments, LP

Milestone Pharmaceuticals Inc. announced that it expects to receive $24.933448 million in funding from RTW Investments, LP

New 90-day high - US$8.91